Kailera Therapeutics/$KLRA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Kailera Therapeutics
Kailera Therapeutics, Inc. is a clinical‑stage biotechnology company focused on developing therapies for obesity and related metabolic conditions; it is advancing four clinical‑stage product candidates delivered via injectable peptides, oral peptides, and oral small molecules . The most notable programs include KAI‑9531 (also known as ribupatide), a once‑weekly injectable GLP‑1/GIP receptor dual agonist, along with KAI‑7535, an oral small‑molecule GLP‑1 receptor agonist, and KAI‑4729, a once‑weekly injectable GLP‑1/GIP/glucagon receptor tri‑agonist . Founded in 2024 and headquartered in Waltham, Massachusetts, Kailera obtained exclusive rights to its pipeline candidates outside Greater China through a collaboration with Jiangsu Hengrui Pharmaceuticals, leveraging Hengrui’s clinical data from trials conducted in China . The company successfully completed its initial public offering and began trading on the Nasdaq Global Select Market under the ticker KLRA in April 2026 . Its strategic positioning rests on its obesity‑specific therapeutic focus, multiple administration modalities in its pipeline, and global reach supported by its in‑licensing arrangement with Hengrui .
Ticker
$KLRA
Sector
Primary listing
Employees
145
Headquarters
Website
KLRA Metrics
BasicAdvanced
$2.9bn
-
-$7,005.54
-
-
Price and volume
Market cap
$2.9bn
Financial strength
Current ratio
9.671
Quick ratio
9.526
Long term debt to equity
1.685
Total debt to equity
1.869
Profitability
EBITDA (TTM)
-222.194
Management effectiveness
Valuation
Free cash flow per share (TTM)
-5,755.918
Growth
What the Analysts think about KLRA
Analyst ratings (Buy, Hold, Sell) for Kailera Therapeutics stock.
KLRA Financial Performance
Revenues and expenses
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs